Home / Market News / $KOD

$KOD news and market catalysts

The 17 most recent market catalysts affecting $KOD, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

17 catalysts 6 high impact 11 bullish 1 bearish Biotechnology
Nov 13, 2026 Corporate Catalyst Bullish Impact 55
UBS Analyst Raises Price Target for Kodiak Sciences
UBS analyst Michael Yee raised the price target for Kodiak Sciences (KOD) from $120 to $150, reaffirming a bullish stance. This is significant as it indicates a prominent analyst s…
Nov 12, 2026 Corporate Catalyst Neutral Impact 92
Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2026 Financial Results
Kodiak Sciences reported a third-quarter 2026 loss per share of $1.05, which was worse than the analyst consensus estimate of a $1.01 loss per share. This earnings miss indicates t…
Oct 20, 2026 Corporate Catalyst Neutral Impact 55
Kodiak Sciences Files Shelf Prospectus For Offering; Size Not Disclosed
Kodiak Sciences filed a shelf prospectus, a standard regulatory filing that allows a company to register a certain amount of securities for sale at a later date without having to f…
Oct 12, 2026 Corporate Catalyst Bullish Impact 55
HC Wainwright & Co. Maintains Buy on Kodiak Sciences, Raises Price Target to $126
HC Wainwright & Co. analyst Matthew Caufield maintained a 'Buy' rating on Kodiak Sciences and significantly raised the price target from $96 to $126. This action signals a strong v…
Sep 28, 2026 Corporate Catalyst Bullish Impact 55
UBS Maintains Buy on Kodiak Sciences, Raises Price Target to $120
UBS analyst Michael Yee maintained a 'Buy' rating on Kodiak Sciences and significantly raised the price target from $80 to $120. This upward revision indicates increased confidence…
Sep 28, 2026 Market Technicals Bullish Impact 65
12 Health Care Stocks Moving In Monday's Intraday Session
This filing, generated by an automated content engine, reports on the intraday performance of 12 health care stocks. The significant percentage changes, particularly Kodiak Science…
Sep 28, 2026 Corporate Catalyst Bullish Impact 55
HC Wainwright & Co. Maintains Buy on Kodiak Sciences, Raises Price Target to $96
HC Wainwright & Co. analyst Matthew Caufield has maintained a 'Buy' rating on Kodiak Sciences (KOD) and raised the price target from $58 to $96. This significant increase in the pr…
Sep 28, 2026 Corporate Catalyst Bullish Impact 95
Kodiak Sciences Says Eye Drug on Par with Regeneron's Medicine
Kodiak Sciences' announcement of positive Phase 3 DAYBREAK trial results for Zenkuda is a major catalyst. The drug demonstrated non-inferiority to Regeneron's Eylea, a market leade…
Sep 28, 2026 Corporate Catalyst Bullish Impact 95
Kodiak Sciences shares are trading higher after the company announced that the primary endpoints were met for Zenkuda and tabirafusp-ted in the Phase 3 DAYBREAK study in patients with wet age-related macular degeneration.
The successful Phase 3 DAYBREAK study for Kodiak Sciences' Zenkuda and tabirafusp-ted is a significant positive catalyst for the company. Meeting primary endpoints de-risks their p…
Sep 28, 2026 Corporate Catalyst Bullish Impact 85
Kodiak Sciences Says Phase 3 DAYBREAK Study Met Primary Endpoints With Zenkuda (Tarcocimab Tedromer) And Tabirafusp-ted (KSI-501) Showing Non-inferiority In Vision Gains For Wet Age-related Macular Degeneration Vs. Aflibercept At Year One
Kodiak Sciences reported that its two investigational drugs, Zenkuda and Tabirafusp-ted, successfully met their primary endpoints in Phase 3 studies for wet age-related macular deg…
Sep 25, 2026 Corporate Catalyst Neutral Impact 95
Kodiak Sciences To Host Webcast To Report Phase 3 DAYBREAK Topline Results For Wet AMD Candidates On September 28 At 8:30 AM Eastern Time
Kodiak Sciences is set to release topline results from its Phase 3 DAYBREAK study for two wet AMD candidates, Zenkuda and KSI-501, on September 28, 2026. This is a critical event f…
Sep 24, 2026 Corporate Catalyst Neutral Impact 55
Goldman Sachs Reinstates Neutral on Kodiak Sciences, Announces $36 Price Target
Goldman Sachs analyst Andrea Newkirk has reinstated coverage on Kodiak Sciences (KOD) with a 'Neutral' rating and a $36 price target. This event is significant as it provides an up…
Sep 17, 2026 Corporate Catalyst Neutral Impact 55
HC Wainwright & Co. Reiterates Buy on Kodiak Sciences, Maintains $58 Price Target
HC Wainwright & Co. analyst Matthew Caufield has reaffirmed his 'Buy' rating and $58 price target for Kodiak Sciences. This is a continuation of an existing positive stance, rather…
Aug 13, 2026 Corporate Catalyst Bearish Impact 92
Kodiak Sciences Q2 EPS $(1.05) Misses $(0.95) Estimate
Kodiak Sciences announced its Q2 earnings, reporting a loss of $(1.05) per share, which was 10.53% worse than the analyst consensus of $(0.95). This significant miss indicates that…
Aug 10, 2026 Corporate Catalyst Bullish Impact 65
Kodiak Sciences Enrols First Patients In Global Phase 3 ALTO Trial Evaluating KSI-501 In Patients With Diabetic Macular Edema
Kodiak Sciences has initiated a crucial Phase 3 trial for KSI-501, a bispecific therapy targeting diabetic macular edema (DME). This is a significant step for the precommercial com…
Aug 6, 2026 Corporate Catalyst Bullish Impact 75
Kodiak Sciences Announces Completion Of 300-Patient Enrollment In First Pivotal Cohort Of Phase 3 PEAK Trial For KSI-101; Says Topline Data On Track For December 2026
This announcement is a significant positive for Kodiak Sciences (KOD) as it marks a crucial step in the drug development process, reducing clinical trial risk and providing a clear…
Aug 3, 2026 Corporate Catalyst Bullish Impact 65
JP Morgan Maintains Overweight on Kodiak Sciences, Raises Price Target to $66
JP Morgan analyst Anupam Rama has maintained an 'Overweight' rating on Kodiak Sciences and raised the price target from $56 to $66. This action signals increased confidence from a …
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.